rs11568821 — LOC105373977 PDCD1/LOC105373977 PD1.3

PDCD1/PD1.3 — The Immune Checkpoint Regulator

PD-1 (Programmed Death-1, encoded by PDCD1) is one of the immune system's most powerful braking mechanisms. Expressed on activated T cells, PD-1 binds its ligands PD-L1 and PD-L2 on antigen-presenting cells and peripheral tissues, suppressing T-cell activation and preventing immune attacks on self-tissue. When this brake is too strong, it enables cancer cells to evade immunity — which is why PD-1 blockade therapies (pembrolizumab, nivolumab) have revolutionised oncology. But when the brake is too weak or dysregulated, autoreactive T cells escape suppression and attack the body's own organs.

The rs11568821 variant, historically named PD1.3¹¹ PD1.3
Named by Prokunina et al. who systematically catalogued PDCD1 polymorphisms in 2002, sits within an intronic enhancer element of the PDCD1 locus at chromosome 2q37.3. It also falls within 2 kb upstream of the long non-coding RNA LOC105373977, which may contribute independent regulatory effects. The G allele at this position is classified as a risk factor for systemic lupus erythematosus (SLE) and as a modifier of multiple sclerosis (MS) disease progression in ClinVar.

The Mechanism

The PD1.3 position falls within an intronic enhancer element in PDCD1's fifth intron²² element in PDCD1's fifth intron
Intronic enhancers are cis-regulatory sequences within gene introns that loop to promoters and control transcription factor recruitment. The G allele disrupts a consensus binding motif for RUNX1³³ RUNX1
RUNX1 (runt-related transcription factor 1) is expressed in immune cells and regulates the expression of numerous immune-function genes including T-cell inhibitory receptors, a transcription factor with broad regulatory roles in haematopoietic and immune cell development. The C allele preserves the RUNX1 binding site; the G allele disrupts it. Because RUNX1 is thought to drive PDCD1 expression through this enhancer, the G allele likely reduces PDCD1 transcription in activated T cells — meaning G allele carriers produce less PD-1 on their T-cell surface, weakening the immune checkpoint and increasing the likelihood that autoreactive T cells escape suppression.

This is the same general class of mechanism as other well-validated autoimmune checkpoint variants: rs3087243 in CTLA4 reduces a different immune brake by destabilising CTLA-4 mRNA, and rs2476601 in PTPN22 impairs an intracellular phosphatase that damps T-cell receptor signalling. All three variants weaken different layers of peripheral T-cell tolerance, and carrying multiple risk variants compounds susceptibility across multiple autoimmune diseases.

The Evidence

The original discovery by Prokunina et al. (2002)⁴⁴ Prokunina et al. (2002)
Nature Genetics — first genome-wide analysis of PDCD1 polymorphisms and SLE susceptibility in Swedish, European-American, and Mexican cohorts found the G allele (reported in that paper as the 'A' allele in minus-strand notation, hence "PD1.3 G/A" in much of the older literature) at approximately 12% in European SLE patients versus 5% in European healthy controls, with a relative risk of 2.6 in Europeans and 3.5 in Mexicans. This was a landmark paper establishing that a non-coding intronic variant in a negative immune regulator could confer meaningful autoimmune susceptibility.

Population-specific effects⁵⁵ Population-specific effects
Different populations show variable LD between PD1.3 and other PDCD1 variants, which may explain why the same G allele appears protective in some cohorts are a notable feature of this locus. A large Spanish cohort study (518 SLE patients, 800 controls) found the opposite association: the G allele was less frequent in Spanish female SLE patients (OR 0.67). The authors attributed this to different haplotype backgrounds in the Spanish versus Northern European and Mexican populations — the risk conferred by PD1.3 appears to depend on which other PDCD1 variants it travels with.

For multiple sclerosis, ClinVar records the G allele as a modifier of disease progression (RCV000009833), and a 2023 case-control study of 229 MS patients⁶⁶ 2023 case-control study of 229 MS patients
Hassani et al., Immunol Med, 229 MS patients and 246 controls found trends consistent with a modest risk contribution, though the effect did not reach conventional significance thresholds in that sample.

An Egyptian female cohort (70 SLE patients, 80 controls) found GG homozygotes enriched among SLE patients (67.1% in patients vs controls, p=0.023)⁷⁷ SLE patients (67.1% in patients vs controls, p=0.023)
Abo El-Khair et al. 2019, Lupus — the G allele frequency was 82.1% in SLE cases, p=0.0021, with strong linkage disequilibrium between PD1.3 and a second PDCD1 variant. This study's finding that the major GG genotype was risk-enriched illustrates how population-stratified haplotypes complicate interpretation at this locus.

It is important to note that multiple studies — including a Southern Brazilian cohort of 95 SLE patients and 87 RA patients — found no significant association⁸⁸ no significant association
PD1.3 A allele frequencies 0.095 in SLE, 0.115 in RA, 0.078 in controls — differences not statistically significant. The overall evidence for rs11568821 is moderate: biologically plausible, replicated in some populations, but inconsistent across cohorts and ancestry groups.

Practical Implications

Carrying the G allele at rs11568821 is not a diagnosis or a certainty of autoimmune disease. The risk increase is moderate (relative risk approximately 1.5–2.6 in populations where the association holds), and the G allele is rare enough (approximately 2–5% in most European populations) that most carriers never develop SLE or MS.

The clinical value of this variant lies in cumulative risk profiling: if you also carry risk variants in CTLA4 (rs3087243 GG), PTPN22 (rs2476601 AT), or STAT4 (rs7574865 TT), the combined signal is more informative than any single variant. Women carry substantially higher lifetime risk for SLE (9:1 female predominance), so the G allele is most clinically relevant for women with a personal or family history of autoimmune disease.

For PD-1 checkpoint immunotherapy: some evidence suggests that germline variation in PDCD1 may influence the balance between immunotherapy efficacy and autoimmune side effects, though this pharmacogenomic connection is not yet established at the clinical level.

Interactions

The PD1.3 variant operates within a broader PDCD1 haplotype context. rs2227981 (PD1.5 C/T)⁹⁹ rs2227981 (PD1.5 C/T)
A second PDCD1 variant in an exonic position that has been studied alongside PD1.3 in haplotype analyses and rs36084323 (PD1.1 G/A) are studied alongside rs11568821 in haplotype analyses; the GACT haplotype (combining all four common PDCD1 variants) showed the strongest SLE association in an Iranian cohort (OR 9.76, p<0.001). These variants are in linkage disequilibrium with each other and the risk they collectively confer is greater than any single variant.

The broader autoimmune checkpoint landscape includes CTLA4 rs3087243 (T-cell co-stimulatory brake) and PTPN22 rs2476601 (T-cell receptor signalling phosphatase) — both expressed in the same T-cell tolerance pathway. Carriers of G alleles at rs11568821 alongside risk alleles at these other immune checkpoint genes face compounding susceptibility to multiple autoimmune conditions, especially SLE and RA.